Studies suggest that patients with FLT3 -ITD have significantly elevated peripheral blood white cell counts and increased bone marrow blasts at diagnosis. Furthermore, they have a significantly higher induction death rate, increased relapse risk, inferior event-free survival, and decreased overall ...
同时,该研究验证了FLT3-ITD突变作为MRD标志物的效用,是支持基于MRD的HCT后吉瑞替尼维持治疗有效性的最早的研究数据之一。 参考文献 Levis MJ, Hamadani M, Logan B, et al. Gilteritinib as Post-Transplant Maintenance for Acute Myel...
在一项前瞻性研究中,198例CBF-AML患者接受两种不同的诱导方案治疗,然后根据治疗反应进行allo-HCT;多变量分析显示,同时存在KIT或FLT3-ITD突变无不良影响。 鉴于报告相互矛盾、实践建议存在差异以及缺乏明确数据,作者通常只考虑下列患者进行移植:CBF突变...
1 The presence of an FLT3-ITD mutation confers a poor risk for patients with AML, with worse outcomes in diseasefree and overall survival.3 In recently updated joint guidelines, the College of American Pathologists and the American Society of Hematology strongly recommend testing all pediatric and...
Further, FLT3-ITD has not been systematically analyzed for outcome from Indian subcontinent. Amongst 64 consecutive pediatric AML patients, FLT3-ITD was present in 12 (19%) patients. All patients with FLT3-ITD achieved CR; those with FLT3-ITD mutation had inferior DFS (P = .029). FLT3 ...
aFLT3mutation in the tyrosine kinase domain (FLT3-TKD), which has a lower incidence in AML (approximately 7–10% of all cases), is uncertain. Accumulating evidence demonstrates thatFLT3mutational status evolves throughout the disease continuum. This so-called clonal evolution, together with the ...
With regards to adult APL patients, 22.2 and 32.6% of the patients showed FLT3 and NPM1 mutation, respectively. In the pediatrics age group ( and mutations. 展开 关键词: AML FLT3 mutations NPM1 mutations DOI: 10.1007/s00277-012-1509-z 被引量: 18 ...
AML in the randomized clinical trial, providing the first solid evidence for the success of maintenance post allo-SCT in AML patients [129], and Phase III MORPHO Trial is under way to evaluate gilteritinib as maintenance after allo-SCT in patients with FLT3 mutation-positive AML (NCT02997202...
associated with the drug. The other issue was the durability of the responses, and when we looked at why that happened, it was due to new mutations inFLT3. That’s kind of good, and that’s kind of bad. It tells you that you’re actually hittingFLT3if you see a new mutation that ...
Background: FMS-like tyrosine kinase 3 gene (FLT3) mutations occur in approximately 30% of all AML patients and carries poor prognosis. Incorporating FLT3 inhibitors with chemotherapy and stem cell transplant (SCT) are treatment strategies attempted to improve outcome. We reviewed our experience to ...